Co-Designing a Consult Patient Decision Aid for Continuation Versus Deprescribing Cholinesterase Inhibitors in People Living with Dementia

• Published in: Drugs & aging 2024-10, Vol.41 (10), p.821-831
• Main Authors: Ailabouni, Nagham J., Thompson, Wade, Hilmer, Sarah N., Quirke, Lyntara, McNeece, Janet, Bourke, Alice, Furst, Chloe, Reeve, Emily
• Format: Article
• Language: English
• Subjects: Audiences; Caregivers; Chronic illnesses; Clinical decision making; Clinical outcomes; Cognitive ability; Consumers; Dementia; Design; Feedback; Geriatrics/Gerontology; Internal Medicine; Medical personnel; Medicine; Medicine & Public Health; Older people; Original; Original Research Article; Parkinson's disease; Patient satisfaction; Pharmacists; Pharmacology/Toxicology; Pharmacotherapy; Professionals; Usability
• ISSN: 1170-229X; 1179-1969; 1179-1969
• DOI: 10.1007/s40266-024-01146-5

Background and Objective As dementia progresses, people living with dementia may take high-risk, unnecessary, or ineffective medicines. Cholinesterase inhibitors (ChEIs) may have benefit in some people with dementia; however, up to one third are continued when no longer necessary or safe. Our aim was to co-design a consult patient decision aid (CPtDA) to support shared decision making between healthcare professionals and consumers about continuing or deprescribing ChEIs. Methods A systematic process was employed to design and test the CPtDA prototype. First, a steering group composed of healthcare professionals and a consumer representative was assembled. Guided by the International Patient Decision Aids Standards, the steering group defined the CPtDA’s purpose, scope, and target audience and drafted the prototype for further testing. Interviews with consumers and healthcare professionals were conducted to gain feedback on the content, format, structure, comprehensibility and usability of the CPtDA prototype. Results After the steering group developed the CPtDA prototype, interviews were conducted with 11 consumers and six healthcare professionals. The content and format of the decision aid were improved iteratively over three rounds after consolidating the feedback at each round. The main changes included rewording the purpose of the decision aid and simplifying its layout and format. Participants reported that the decision aid is comprehensible and may be useful in practice. Conclusions Limited available resources guide shared decision making about deprescribing. This study resulted in a co-designed and alpha-tested CPtDA for people living with dementia and carers to help them review the ongoing need for their ChEIs. Further research is needed to explore using the CPtDA in practice to support people living with dementia and their carers engage in the shared decision-making process about continuing or deprescribing their ChEIs. Our co-designed CPtDA could help people living with dementia and their carers review their goals of care alongside their healthcare professional. This may prompt conversations about appropriately using ChEIs and increase the uptake of deprescribing.